News
NAMSW
18.80
+4.50%
0.81
Weekly Report: what happened at NAMS last week (0601-0605)?
Weekly Report · 6d ago
NewAmsterdam Shareholders Approve ESPP and Governance Proposals
TipRanks · 06/03 12:24
Weekly Report: what happened at NAMS last week (0525-0529)?
Weekly Report · 06/01 10:19
Top NewAmsterdam Pharma Executive Makes Major Cash-Out Move
TipRanks · 05/28 02:03
Weekly Report: what happened at NAMS last week (0518-0522)?
Weekly Report · 05/25 10:22
Weekly Report: what happened at NAMS last week (0511-0515)?
Weekly Report · 05/18 10:22
Analysts’ Top Healthcare Picks: Halozyme (HALO), MindWalk Holdings (HYFT)
TipRanks · 05/12 11:01
Analysts Conflicted on These Healthcare Names: Treace Medical Concepts (TMCI), NewAmsterdam Pharma Company (NAMS) and LENSAR (LNSR)
TipRanks · 05/11 13:30
Weekly Report: what happened at NAMS last week (0504-0508)?
Weekly Report · 05/11 10:19
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May
Barchart · 05/11 07:41
Monster Beverage, Westrock Coffee, Himax Technologies And Other Big Stocks Moving Higher On Friday
Benzinga · 05/08 14:15
Guggenheim Sticks to Their Buy Rating for NewAmsterdam Pharma Company (NAMS)
TipRanks · 05/08 11:39
Analysts Are Bullish on These Healthcare Stocks: Praxis Precision Medicines (PRAX), NewAmsterdam Pharma Company (NAMS)
TipRanks · 05/07 20:10
Analysts Are Bullish on These Healthcare Stocks: NewAmsterdam Pharma Company (NAMS), Zoetis (ZTS)
TipRanks · 05/07 17:01
H.C. Wainwright Sticks to Their Buy Rating for NewAmsterdam Pharma Company (NAMS)
TipRanks · 05/07 16:45
NewAmsterdam Pharma reports Q1 revenue $3.04M, consensus $925,520
TipRanks · 05/07 14:43
NewAmsterdam Pharma Q1 EPS $(0.40) Beats $(0.47) Estimate, Sales $3.040M Beat $936.364K Estimate
Benzinga · 05/07 12:41
NewAmsterdam Pharma reports Q1 results
Seeking Alpha · 05/07 11:59
RBC Capital Remains a Buy on NewAmsterdam Pharma Company (NAMS)
TipRanks · 05/06 12:10
Weekly Report: what happened at NAMS last week (0427-0501)?
Weekly Report · 05/04 10:17
More
Webull provides a variety of real-time NAMSW stock news. You can receive the latest news about NewAmsterdam Pha through multiple platforms. This information may help you make smarter investment decisions.
About NAMSW
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.